Signal Genetics receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Viridian Therapeutics Inc (VRDN)
Viridian Therapeutics Inc stock price live, this page displays NASDAQ VRDN stock exchange data. View the VRDN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Viridian Therapeutics Inc real time stock price chart below.
What Is the Viridian Therapeutics Inc Stock Price Today?
The Viridian Therapeutics Inc stock price today is 28.83.
What Is the Stock Symbol for Viridian Therapeutics Inc?
The stock symbol for Viridian Therapeutics Inc is "VRDN."
What Stock Exchange Does Viridian Therapeutics Inc Trade On?
Viridian Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Viridian Therapeutics Inc a Good Stock to Buy?
Determining whether Viridian Therapeutics Inc, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the VRDN quote. (ISIN: US92790C1045)
What Is the Viridian Therapeutics Inc Stock Price Today?
The Viridian Therapeutics Inc stock price today is 28.83.
What Is the Stock Symbol for Viridian Therapeutics Inc?
The stock symbol for Viridian Therapeutics Inc is "VRDN."
What Stock Exchange Does Viridian Therapeutics Inc Trade On?
Viridian Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Viridian Therapeutics Inc a Good Stock to Buy?
Determining whether Viridian Therapeutics Inc, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the VRDN quote. (ISIN: US92790C1045)
28.83
-0.23(-0.77%)
Real-time Data·
Fair Value
An estimate of a Viridian Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
28.48
29.61
52 wk Range
13.18
34.29
VRDN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Viridian Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
28.4829.61
52 wk Range
13.1834.29
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
VRDN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Viridian Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
36.20
Upside
+25.56%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
RSI suggests the stock is in overbought territory
Signal Genetics receives Investment Bank Analyst Rating Update- Investing.com
Pro
Signal Genetics receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Signal Genetics receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Signal Genetics receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Signal Genetics receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Signal Genetics receives Investment Bank Analyst Rating Update- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
17 Buy
0 Hold
0 Sell
Ratings:
17 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 36.20
(+25.56% Upside)
Viridian Therapeutics Inc SWOT Analysis
TED Market Disrupto | Viridian Therapeutics challenges the thyroid eye disease treatment landscape with VRDN-001, poised to compete against Amgen's Tepezza |
Pipeline Promise | Explore Viridian's diverse portfolio, including subcutaneous formulations and FcRn inhibitors, positioning the company for long-term growth beyond TED |
Financial Fortitude | Learn about Viridian's robust financial health, with a cash runway extending into 2027 and a remarkable current ratio of 18.55 |
Analyst Optimism | Delve into analyst perspectives, with price targets ranging from $22 to $61, reflecting potential upside for this pre-revenue biotech company |
Viridian Therapeutics Inc Earnings Call Summary for Q3/2026
- Viridian posted Q3 revenue of $25.75M vs. $4.68M expected, driven by LUMVOA's $24.7M debut; loss of $0.81/share beat estimates by 21%
- LUMVOA launch exceeded expectations with 100+ patients starting therapy by Sept. 30; shares surged 9.09% to $27.44 in premarket trading
- Company holds $955M in cash with strong liquidity (16.95 current ratio), sufficient to fund operations through profitability per management
- Payer coverage reached 30% of U.S. lives; broad coverage expected within 6-9 months; permanent J-code effective Jan. 1, 2027
- Elegrobart BLA submission targeted for Q1 2027; VRDN-292 entering Phase 1 trials; management expects continued patient growth in Q4
Last Updated: 04/11/2026, 14:48
Read Full TranscriptEarnings
Latest Release
Nov 04, 2026
EPS / Forecast
-0.81 / -1.02
Revenue / Forecast
25.75M / 4.68M
Compare VRDN to Peers and Sector
Metrics to compare | VRDN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVRDNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −8.2x | −1.5x | −0.2x | |
PEG Ratio | −3.33 | −0.05 | 0.00 | |
Price/Book | 6.7x | 4.0x | 2.6x | |
Price / LTM Sales | 122.9x | 13.3x | 2.8x | |
Upside (Analyst Target) | 23.7% | 72.9% | 62.7% | |
Fair Value Upside | Unlock | 19.1% | 8.0% | Unlock |
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves’ disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Viridian Therapeutics (VRDN) Stock Price Today?
The Viridian Therapeutics stock price today is 28.83 USD.
What Stock Exchange Does Viridian Therapeutics Trade On?
Viridian Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Viridian Therapeutics?
The stock symbol for Viridian Therapeutics is "VRDN."
What Is the Viridian Therapeutics (VRDN) Afterhours Price Today? (Afterhours variable test: 29.72) Current Date: Nov 05, 2026
After hours price: 29.72. After hours price change (units): 0.66. Price change percentage: 2.29%
What Is the Viridian Therapeutics Market Cap?
As of today, Viridian Therapeutics market cap is 3.27B USD.
What Is Viridian Therapeutics's Earnings Per Share (TTM)?
The Viridian Therapeutics EPS (TTM) is -3.76.
When Is the Next Viridian Therapeutics Earnings Date?
Viridian Therapeutics will release its next earnings report on Mar 11, 2027.
From a Technical Analysis Perspective, Is VRDN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Viridian Therapeutics Stock Split?
Viridian Therapeutics has split 2 times.
How Many Employees Does Viridian Therapeutics Have?
Viridian Therapeutics has 252 employees.
What is the current trading status of Viridian Therapeutics (VRDN)?
As of Nov 05, 2026, Viridian Therapeutics (VRDN) is trading at a price of 28.83 USD, with a previous close of 29.06 USD. The stock has fluctuated within a day range of 28.48 USD to 29.61 USD, while its 52-week range spans from 13.18 USD to 34.29 USD.
What Is Viridian Therapeutics (VRDN) Price Target According to Analysts?
The average 12-month price target for Viridian Therapeutics is 36.20 USD, with a high estimate of 50 USD and a low estimate of 22 USD. 17 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +25.56% Upside potential.
What Is the VRDN Premarket Price?
VRDN's last pre-market stock price is 29.57 USD. The pre-market share volume is 5,130.00, and the stock has decreased by 0.52, or 1.77%.
What Is the VRDN After Hours Price?
VRDN's last after hours stock price is 29.72 USD, the stock has decreased by 0.66, or 2.29%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.